Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20030009214 A1
Publication typeApplication
Application numberUS 10/231,007
Publication dateJan 9, 2003
Filing dateAug 30, 2002
Priority dateMar 30, 1998
Also published asCA2323358A1, CA2323358C, CA2640588A1, CA2640588C, DE69931403D1, DE69931403T2, DE69931403T3, DE69937879D1, DE69937879T2, DE69938159D1, DE69938159T2, DE69939283D1, EP1071490A1, EP1071490B1, EP2286865A1, EP2286865B1, EP2289593A1, EP2292181A1, US6241762, US6562065, US7279004, US7819912, US7896912, US8052734, US8052735, US8623068, US20030167085, US20040122505, US20040193249, US20050159806, US20050203609, US20060136038, US20070067026, US20080109071, US20080243070, US20080249609, US20080294242, US20120083873, WO1999049928A1
Publication number10231007, 231007, US 2003/0009214 A1, US 2003/009214 A1, US 20030009214 A1, US 20030009214A1, US 2003009214 A1, US 2003009214A1, US-A1-20030009214, US-A1-2003009214, US2003/0009214A1, US2003/009214A1, US20030009214 A1, US20030009214A1, US2003009214 A1, US2003009214A1
InventorsJohn Shanley
Original AssigneeShanley John F.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Medical device with beneficial agent delivery mechanism
US 20030009214 A1
Abstract
An expandable tissue supporting device of the present invention employs ductile hinges at selected points in the expandable device. When expansion forces are applied to the device as a whole, the ductile hinges concentrate expansion stresses and strains in small well defined areas. The expandable medical device including ductile hinges provides the advantages of low expansion force requirements, relatively thick walls which are radio-opaque, improved crimping properties, high crush strength, reduced elastic recoil after implantation, and control of strain to a desired level. The expandable tissue supporting device includes a plurality of elongated beams arranged in a cylindrical device and connected together by a plurality of ductile hinges. Although many ductile hinge configurations are possible, the ductile hinges preferably have a substantially constant hinge cross sectional area which is smaller than a beam cross sectional area such that as the device is expanded from a first diameter to a second diameter, the ductile hinges experience plastic deformation while the beams are not plastically deformed.
Images(11)
Previous page
Next page
Claims(26)
What is claimed is:
1. An expandable medical device comprising:
a plurality of elongated beams, the plurality of elongated beams joined together to form a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter, the plurality of elongated beams each having a beam width in a circumferential direction; and
a plurality of ductile hinges connecting the plurality of beams together in the substantially cylindrical device, the ductile hinges having a substantially constant width in a circumferential dimension along a portion of a hinge length which is at least {fraction (1/3)} a total hinge length, wherein the hinge width is smaller than the beam width such that as the device is expanded from the first diameter to the second diameter the ductile hinges experience plastic deformation while the beams are not plastically deformed.
2. The expandable medical device according to claim 1, further comprising an abrupt transition between each of the elongated beams and each of the ductile hinges.
3. The expandable medical device according to claim 1, further comprising a plurality of axial slots between adjacent elongated beams and a plurality of circumferential slots, wherein the plurality of ductile hinges are each formed between an axial slot and a circumferential slot.
4. The expandable medical device according to claim 3, wherein the ductile hinges are formed at opposite ends of the circumferential slots.
5. The expandable medical device according to claim 1, wherein the ductile hinges are each in the shape of a curved prismatic beam.
6. The expandable medical device according to claim 5, wherein the curved prismatic beams are positioned such that during stent expansion, tensile strain is distributed along a convex surface of the curved prismatic beam.
7. The expandable medical device according to claim 1, wherein the plurality of elongated beams are formed of wire and the plurality of ductile hinges are reduced diameter portions of the wire.
8. The expandable medical device according to claim 1, wherein expansion of the substantially cylindrical device from the first diameter to the second diameter which is at least two times the first diameter results in substantially no axial contraction.
9. The expandable medical device according the claim 1, further comprising a geometric deflection limiting feature for limiting an amount of bending of the ductile hinges.
10. The expandable medical device according to claim 9, wherein the geometric deflection limiting feature is a V-shaped notch having side surfaces which contact each other when a maximum amount of bending is reached.
11. The expandable medical device according to claim 1, wherein the plurality of elongated beams extend substantially axially and a plurality of circumferential beams are each connected at first and second ends to one of the axial beams by a ductile hinge.
12. An expandable medical device comprising:
a cylindrical tube;
a plurality of axial slots formed in the cylindrical tube in a staggered arrangement to define a network of elongated struts, wherein each of the elongated struts are axially displaced from adjacent struts; and
a plurality of ductile hinges formed between the elongated struts, the ductile hinges allowing the cylindrical tube to be expanded or compressed from a first diameter to a second diameter by deformation of the ductile hinges, the ductile hinges being asymmetrically configured to reach a predetermined strain level upon a first percentage expansion and to reach the predetermined strain level upon a second percentage of compression, wherein the first percentage is larger than the second percentage.
13. The expandable medical device according to claim 12, wherein the elongated struts have a substantially constant width in a circumferential direction, and the ductile hinges have a width in the circumferential direction which is less than {fraction (2/3)} the width of the struts.
14. The expandable medical device according to claim 13, wherein a transition between the cross sectional area of the struts and the cross sectional area of the ductile hinges is an abrupt transition which extends less than 10 percent of a length of a strut.
15. The expandable medical device according to claim 12, wherein the plurality of ductile hinges are curved prismatic beams having a convex side surface and a concave side surface.
16. The expandable medical device according to claim 12, wherein a ratio of a length of the ductile hinges to a length of the axial struts is 1:6 or less.
17. The expandable medical device according to claim 12, further comprising a geometric deflection limiting feature for limiting an amount of bending of the ductile hinges.
18. The expandable medical device according to claim 12, wherein the ductile hinges are designed to deform plastically upon radial expansion or compression of the expandable medical device while the elongated struts experience no plastic deformation upon radial expansion or compression.
19. The expandable medical device according to claim 12, wherein the expandable medical device is formed of Nitinol, and the ductile hinges are designed to deform upon radial expansion or compression of the expandable medical device and can be returned to an original configuration by heating.
20. The expandable medical device according to claim 12, wherein the elongated struts include a beneficial agent for delivery to a patient.
21. An expandable medical device comprising:
a plurality of elongated beams having a substantially constant beam cross sectional area along a beam length;
a plurality of ductile hinges connecting the plurality of beams together in a substantially cylindrical device which is expandable or compressible from a first diameter to a second diameter by plastic deformation of the ductile hinges; and
a plurality of deflection limiting members positioned at a plurality of the ductile hinges to limit the deflection at the ductile hinges.
22. The expandable medical device according to claim 21, wherein the deflection limiting members include angled side walls on opposite sides of a ductile hinge which engage one another to limit deflection at ductile hinge.
23. The expandable medical device according to claim 22, wherein the deflection limiting members are V-shaped notches.
24. An expandable medical device which is visible in x-ray and fluoroscope images, the device comprising:
a plurality of struts arranged to form an expandable cylindrical tube; and
a plurality of ductile hinges connecting the plurality of struts, wherein the struts and ductile hinges have a thickness in a radial direction of the cylindrical tube of at least 0.003 inches (0.0762 mm).
25. The expandable medical device according to claim 24, wherein the device is formed of stainless steel.
26. The expandable medical device according to claim 24, wherein the thickness of the struts and ductile hinges is at least 0.005 inches (0.127 mm).
Description
    BACKGROUND OF THE INVENTION
  • [0001]
    1. Field of the Invention
  • [0002]
    The present invention relates to tissue-supporting medical devices, and more particularly to expandable, non-removable devices that are implanted within a bodily lumen of a living animal or human to support the organ and maintain patency.
  • [0003]
    2. Summary of the Related Art
  • [0004]
    In the past, permanent or biodegradable devices have been developed for implantation within a body passageway to maintain patency of the passageway. These devices are typically introduced percutaneously, and transported transluminally until positioned at a desired location. These devices are then expanded either mechanically, such as by the expansion of a mandrel or balloon positioned inside the device, or expand themselves by releasing stored energy upon actuation within the body. Once expanded within the lumen, these devices, called stents, become encapsulated within the body tissue and remain a permanent implant.
  • [0005]
    Known stent designs include monofilament wire coil stents (U.S. Pat. No. 4,969,458); welded metal cages (U.S. Pat. Nos. 4,733,665 and 4,776,337); and, most prominently, thin-walled metal cylinders with axial slots formed around the circumference (U.S. Pat. Nos. 4,733,665, 4,739,762, and 4,776,337). Known construction materials for use in stents include polymers, organic fabrics and biocompatible metals, such as, stainless steel, gold, silver, tantalum, titanium, and shape memory alloys such as Nitinol.
  • [0006]
    U.S. Pat. Nos. 4,733,665, 4,739,762, and 4,776,337 disclose expandable and deformable interluminal vascular grafts in the form of thin-walled tubular members with axial slots allowing the members to be expanded radially outwardly into contact with a body passageway. After insertion, the tubular members are mechanically expanded beyond their elastic limit and thus permanently fixed within the body. The force required to expand these tubular stents is proportional to the thickness of the wall material in a radial direction. To keep expansion forces within acceptable levels for use within the body (e.g., 5-10 atm), these designs must use very thin-walled materials (e.g., stainless steel tubing with 0.0025 inch thick walls). However, materials this thin are not visible on conventional fluoroscopic and x-ray equipment and it is therefore difficult to place the stents accurately or to find and retrieve stents that subsequently become dislodged and lost in the circulatory system.
  • [0007]
    Further, many of these thin-walled tubular stent designs employ networks of long, slender struts whose width in a circumferential direction is two or more times greater than their thickness in a radial direction. When expanded, these struts are frequently unstable, that is, they display a tendency to buckle, with individual struts twisting out of plane. Excessive protrusion of these twisted struts into the bloodstream has been observed to increase turbulence, and thus encourage thrombosis. Additional procedures have often been required to attempt to correct this problem of buckled struts. For example, after initial stent implantation is determined to have caused buckling of struts, a second, high-pressure balloon (e.g., 12 to 18 atm) would be used to attempt to drive the twisted struts further into the lumen wall. These secondary procedures can be dangerous to the patient due to the risk of collateral damage to the lumen wall.
  • [0008]
    Many of the known stents display a large elastic recovery, known in the field as “recoil,” after expansion inside a lumen. Large recoil necessitates over-expansion of the stent during implantation to achieve the desired final diameter. Over-expansion is potentially destructive to the lumen tissue. Known stents of the type described above experience recoil of up to about 6 to 12% from maximum expansion.
  • [0009]
    Large recoil also makes it very difficult to securely crimp most known stents onto delivery catheter balloons. As a result, slippage of stents on balloons during interlumenal transportation, final positioning, and implantation has been an ongoing problem. Many ancillary stent securing devices and techniques have been advanced to attempt to compensate for this basic design problem. Some of the stent securing devices include collars and sleeves used to secure the stent onto the balloon.
  • [0010]
    Another problem with known stent designs is non-uniformity in the geometry of the expanded stent. Non-uniform expansion can lead to non-uniform coverage of the lumen wall creating gaps in coverage and inadequate lumen support. Further, over expansion in some regions or cells of the stent can lead to excessive material strain and even failure of stent features. This problem is potentially worse in low expansion force stents having smaller feature widths and thicknesses in which manufacturing variations become proportionately more significant. In addition, a typical delivery catheter for use in expanding a stent includes a balloon folded into a compact shape for catheter insertion. The balloon is expanded by fluid pressure to unfold the balloon and deploy the stent. This process of unfolding the balloon causes uneven stresses to be applied to the stent during expansion of the balloon due to the folds causing the problem non-uniform stent expansion.
  • [0011]
    U.S. Pat. No. 5,545,210 discloses a thin-walled tubular stent geometrically similar to those discussed above, but constructed of a nickel-titanium shape memory alloy (“Nitinol”). This design permits the use of cylinders with thicker walls by making use of the lower yield stress and lower elastic modulus of martensitic phase Nitinol alloys. The expansion force required to expand a Nitinol stent is less than that of comparable thickness stainless steel stents of a conventional design. However, the “recoil” problem after expansion is significantly greater with Nitinol than with other materials. For example, recoil of a typical design Nitinol stent is about 9%. Nitinol is also more expensive, and more difficult to fabricate and machine than other stent materials, such as stainless steel.
  • [0012]
    All of the above stents share a critical design property: in each design, the features that undergo permanent deformation during stent expansion are prismatic, i.e., the cross sections of these features remain constant or change very gradually along their entire active length. To a first approximation, such features deform under transverse stress as simple beams with fixed or guided ends: essentially, the features act as a leaf springs. These leaf spring like structures are ideally suited to providing large amounts of elastic deformation before permanent deformation commences. This is exactly the opposite of ideal stent behavior. Further, the force required to deflect prismatic stent struts in the circumferential direction during stent expansion is proportional to the square of the width of the strut in the circumferential direction. Expansion forces thus increase rapidly with strut width in the above stent designs. Typical expansion pressures required to expand known stents are between about 5 and 10 atmospheres. These forces can cause substantial damage to tissue if misapplied.
  • [0013]
    [0013]FIG. 1 shows a typical prior art “expanding cage” stent design. The stent 10 includes a series of axial slots 12 formed in a cylindrical tube 14. Each axial row of slots 12 is displaced axially from the adjacent row by approximately half the slot length providing a staggered slot arrangement. The material between the slots 12 forms a network of axial struts 16 joined by short circumferential links 18. The cross section of each strut 16 remains constant or varies gradually along the entire length of the strut and thus the rectangular moment of inertia and the elastic and plastic section moduli of the cross section also remain constant or vary gradually along the length of the strut. Such a strut 16 is commonly referred to as a prismatic beam. Struts 16 in this type of design are typically 0.005 to 0.006 inches (0.127-0.1524 mm) wide in the circumferential direction. Strut thicknesses in the radial direction are typically about 0.0025 inches (0.0635 mm) or less to keep expansion forces within acceptable levels. However, most stent materials must be approximately 0.005 inches (0.127 mm) thick for good visibility on conventional fluoroscopic equipment. This high ratio of strut width to thickness, combined with the relatively high strut length and the initial curvature of the stent tubing combine to cause the instability and bucking often seen in this type of stent design. When expanded, the stent structure of FIG. 1 assumes the roughly diamond pattern commonly seen in expanded sheet metal.
  • [0014]
    Another stent described in PCT publication number WO 96/29028 uses struts with relatively weak portions of locally-reduced cross sections which on expansion of the stent act to concentrate deformation at these areas. However, as discussed above non-uniform expansion is even more of a problem when smaller feature widths and thicknesses are involved because manufacturing variations become proportionately more significant. The locally-reduced cross section portions described in this document are formed by pairs of circular holes. The shape of the locally-reduced cross section portions undesirably concentrates the plastic strain at the narrowest portion. This concentration of plastic strain without any provision for controlling the level of plastic strain makes the stent highly vulnerable to failure.
  • [0015]
    In view of the drawbacks of the prior art stents, it would be advantageous to be able to expand a stent with an expansion force at a low level independent of choice of stent materials, material thickness, or strut dimensions.
  • [0016]
    It would further be advantageous to have a tissue-supporting device that permits a choice of material thickness that could be viewed easily on conventional fluoroscopic equipment for any material.
  • [0017]
    It would also be advantageous to have a tissue-supporting device that is inherently stable during expansion, thus eliminating buckling and twisting of structural features during stent deployment.
  • [0018]
    It would also be desirable to control strain to a desired level which takes advantage of work hardening without approaching a level of plastic strain at which failure may occur.
  • [0019]
    In addition, it would be advantageous to have a tissue-supporting device with minimal elastic recovery, or “recoil” of the device after expansion.
  • [0020]
    It would be advantageous to have a tissue supporting device that can be securely crimped to the delivery catheter without requiring special tools, techniques, or ancillary clamping features.
  • [0021]
    It would further be advantageous to have a tissue-supporting device that has improved resistance to compressive forces (improved crush strength) after expansion.
  • [0022]
    It would also be advantageous to have a tissue-supporting device that achieves all the above improvements with minimal foreshortening of the overall stent length during expansion.
  • SUMMARY OF THE INVENTION
  • [0023]
    The present invention addresses several important problems in expandable medical device design including: high expansion force requirements; lack of radio-opacity in thin-walled stents; buckling and twisting of stent features during expansion; poor crimping properties; and excessive elastic recovery (“recoil”) after implantation. The invention also provides benefits of improved resistance to compressive forces after expansion, control of the level of plastic strain, and low axial shortening during expansion. Some embodiments of the invention also provide improved uniformity of expansion by limiting a maximum geometric deflection between struts. The invention may also incorporate sites for the inclusion of beneficial agent delivery.
  • [0024]
    The invention involves the incorporation of stress/strain concentration features or “ductile hinges” at selected points in the body of an expandable cylindrical medical device. When expansion forces are applied to the device as a whole, these ductile hinges concentrate expansion stresses and strains in small, well-defined areas while limiting strut deflection and plastic strain to specified levels.
  • [0025]
    In accordance with one aspect of the present invention, an expandable medical device includes a plurality of elongated beams having a substantially constant beam cross sectional area along a beam length. The plurality of elongated beams are joined together to form a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter. A plurality of ductile hinges connect the plurality of beams together in the substantially cylindrical device. The ductile hinges have a substantially constant hinge cross sectional area along a substantial portion of a hinge length. The hinge cross sectional area is smaller than the beam cross sectional area such that as the device is expanded from the first diameter to the second diameter the ductile hinges experience plastic deformation while the beams are not plastically deformed.
  • [0026]
    In accordance with a further aspect of the invention, an expandable medical device includes a cylindrical tube, and a plurality of axial slots formed in the cylindrical tube in a staggered arrangement to define a network of elongated struts, wherein each of the elongated struts are axially displaced from adjacent struts. A plurality of ductile hinges are formed between the elongated struts. The ductile hinges allow the cylindrical tube to be expanded or compressed from a first diameter to a second diameter by deformation of the ductile hinges. The ductile hinges are asymmetrically configured to reach a predetermined strain level upon a first percentage expansion and to reach the predetermined strain level upon a second percentage of compression, wherein the first percentage is larger than the second percentage.
  • [0027]
    In accordance with another aspect of the present invention, an expandable medical device includes a plurality of elongated beams having a substantially constant beam cross sectional area along a beam length. A plurality of ductile hinges connect the plurality of beams together in a substantially cylindrical device which is expandable or compressible from a first diameter to a second diameter by plastic deformation of the ductile hinges. A plurality of deflection limiting members are positioned at a plurality of the ductile hinges which limit the deflection at the ductile hinges.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0028]
    The invention will now be described in greater detail with reference to the preferred embodiments illustrated in the accompanying drawings, in which like elements bear like reference numerals, and wherein:
  • [0029]
    [0029]FIG. 1 is an isometric view of a prior art tissue-supporting device;
  • [0030]
    [0030]FIG. 2 is an isometric view of a tissue-supporting device in accordance with one embodiment of the invention;
  • [0031]
    [0031]FIGS. 3a-d are perspective views of ductile hinges according to several variations of the invention;
  • [0032]
    [0032]FIG. 3e is a side view of another embodiment of a ductile hinge;
  • [0033]
    [0033]FIGS. 4a and 4 b are an isometric view and an enlarged side view of a tissue-supporting device in accordance with an alternative embodiment of the invention;
  • [0034]
    [0034]FIGS. 5a-c are perspective, side, and cross-sectional views of an idealized ductile hinge for purposes of analysis;
  • [0035]
    [0035]FIG. 5d is a stress/strain curve for the idealized ductile hinge;
  • [0036]
    FIGS. 6 is a perspective view of a simple beam for purposes of calculation;
  • [0037]
    [0037]FIG. 7 is a moment verses curvature graph for a rectangular beam;
  • [0038]
    [0038]FIG. 8 is an enlarged side view of a bent ductile hinge;
  • [0039]
    [0039]FIGS. 9a and 9 b are enlarged side views of ductile hinges in initial and expanded positions with shortened struts to illustrate axial contraction relationships; and
  • [0040]
    [0040]FIG. 10 is a side view of a portion of an alternative embodiment of a tissue supporting device having a high-crush-strength and low-recoil.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • [0041]
    [0041]FIG. 2 shows one embodiment of an expandable tissue supporting device 20 in accordance with the present invention. The tissue supporting device 20 includes a series of axial slots 22 formed in a cylindrical tube 24. Each axial slot 22 is displaced axially from the slots in adjacent rows of slots by approximately half the slot length resulting in a staggered slot arrangement. The offset between adjacent rows of slots results in alternate rows of slots which extend to the ends of the cylindrical tube 24. At each interior end of each of the axial slots 22 a circumferential slot 26 is formed. The material between the slots 22 forms a network of axial struts 28 extending substantially parallel to an axis of the tube 24. The axial struts 28 are joined by short circumferential links 30. The circumferential links 30 are positioned at both the interior of the cylindrical tube and at the ends of the cylindrical tube. The cross section (and rectangular moment of inertia) of each of the struts 28 is not constant along the length of the strut. Rather, the strut cross section changes abruptly at both ends of each strut 28 at the location of the circumferential slots 26. The struts 28 are thus not prismatic. Each individual strut 28 is linked to the rest of the structure through a pair of reduced sections 32, one at each end, which act as stress/strain concentration features. The reduced sections 32 of the struts function as hinges in the cylindrical structure. Since the stress/strain concentration features 32 are designed to operate into the plastic deformation range of generally ductile materials, they are referred to as ductile hinges. Such features are also commonly referred to as “Notch Hinges” or “Notch Springs” in ultra-precision mechanism design, where they are used exclusively in the elastic range.
  • [0042]
    With reference to the drawings and the discussion, the width of any feature is defined as its dimension in the circumferential direction of the cylinder. The length of any feature is defined as its dimension in the axial direction of the cylinder. The thickness of any feature is defined as the wall thickness of the cylinder.
  • [0043]
    The presence of the ductile hinges 32 allows all of the remaining features in the tissue supporting device to be increased in width or the circumferentially oriented component of their respective rectangular moments of inertia—thus greatly increasing the strength and rigidity of these features. The net result is that elastic, and then plastic deformation commence and propagate in the ductile hinges 32 before other structural elements of the device undergo any significant elastic deformation. The force required to expand the tissue supporting device 20 becomes a function of the geometry of the ductile hinges 32, rather than the device structure as a whole, and arbitrarily small expansion forces can be specified by changing hinge geometry for virtually any material wall thickness. In particular, wall thicknesses great enough to be visible on a fluoroscope can be chosen for any material of interest.
  • [0044]
    In order to get minimum recoil, the ductile hinges 32 should be designed to operate well into the plastic range of the material, and relatively high local strain-curvatures are developed. When these conditions apply, elastic curvature is a very small fraction of plastic or total curvature, and thus when expansion forces are relaxed, the percent change in hinge curvature is very small. When incorporated into a strut network designed to take maximum advantage of this effect, the elastic springback, or “recoil,” of the overall stent structure is minimized.
  • [0045]
    In the embodiment of FIG. 2, it is desirable to increase the width of the individual struts 28 between the ductile hinges 32 to the maximum width that is geometrically possible for a given diameter and a given number of struts arrayed around that diameter. The only geometric limitation on strut width is the minimum practical width of the slots 22 which is about 0.002 inches (0.0508 mm) for laser machining. Lateral stiffness of the struts 28 increases as the cube of strut width, so that relatively small increases in strut width significantly increase strut stiffness. The net result of inserting ductile hinges 32 and increasing strut width is that the struts 28 no longer act as flexible leaf springs, but act as essentially rigid beams between the ductile hinges. All radial expansion or compression of the cylindrical tissue supporting device 20 is accommodated by mechanical strain in the hinge features 32, and yield in the hinge commences at very small overall radial expansion or compression.
  • [0046]
    Yield in ductile hinges at very low gross radial deflections also provides the superior crimping properties displayed by the ductile hinge-based designs. When a tissue supporting device is crimped onto a folded catheter balloon, very little radial compression of the device is possible since the initial fit between balloon and device is already snug. Most stents simply rebound elastically after such compression, resulting in very low clamping forces and the attendant tendency for the stent to slip on the balloon. Ductile hinges, however, sustain significant plastic deformation even at the low deflections occurring during crimping onto the balloon, and therefore a device employing ductile hinges displays much higher clamping forces. The ductile hinge designs according to the present invention may be securely crimped onto a balloon of a delivery catheter by hand or by machine without the need for auxiliary retaining devices commonly used to hold known stents in place.
  • [0047]
    The geometric details of the stress/strain concentration features or ductile hinges 32 can be varied greatly to tailor the exact mechanical expansion properties to those required in a specific application. The most obvious and straightforward ductile hinges are formed by slots or notches with rounded roots, as in FIGS. 3a and 3 c. Since the laser beams often used to fabricate these features are themselves round, slots or notches with circular roots are also among the easiest to fabricate.
  • [0048]
    [0048]FIG. 3a shows a ductile hinge 36 formed by a pair of opposed circular grooves 38, 40. According to this embodiment the circumferential slot 26 has semicircular ends 38 having a radius of curvature r. Outer semicircular grooves 40 opposed the semicircular ends 38 and also have a radius of curvature r. FIG. 3c shows another ductile hinge 54 formed by a parabolic groove 56.
  • [0049]
    Generally, the ductile hinges 36 of the embodiment of FIG. 3a formed between pairs of concave curves 38, 40 have a minimum width along a line connecting their respective centers of curvature. When the struts connected by the ductile hinge are moved apart or together, plastic deformation is highly concentrated in a region immediately adjacent to the plane that bisects the hinge at this narrow point.
  • [0050]
    For smaller deflection, this very high strain concentration at the bisecting plane is acceptable, and in some cases, useful. For stent crimping purposed, for example, it is desirable to generate relatively large plastic deformations at very small deflection angles.
  • [0051]
    As a practical matter, however, strut deflection angles for device expansion are often in the 25 to 45 range. At these angles, strain at the root or bisecting plane of concave ductile hinge features can easily exceed the 50 to 60% elongation-to-failure of 316L stainless steel, one of the most ductile stent materials. Deflection limiting features which will be described further below limit the geometric deflection of struts, but these features do not in themselves affect the propagation pattern of plastic deformation in a given ductile hinge design. For concave ductile hinges at large bend angles, very high strain concentrations remain. Scanning electron micrographs have confirmed this analysis.
  • [0052]
    In many engineering applications, it is desirable to limit the amount of strain, or “cold-work,” in a material to a specified level in order to optimize material properties and to assure safe operation. For example, in medical applications it is desirable to limit the amount of cold-work in 316L stainless steel to about 30%. At this level, the strength of the material is increased, while the material strain is still well below the failure range. Ideally, therefore, a safe and effective ductile hinge should not simply limit gross deflection, but reliably limit material strain to a specified level.
  • [0053]
    [0053]FIG. 3b shows a simple ductile hinge design that allows material strain to be limited to some specified level. The ductile hinge of FIG. 3b is formed by a rectangular circumferential groove 46 with filleted corners 48 on one side of a strut, the opposite side 50 of the strut remaining straight. The ductile hinges 44 are substantially rectangular sections between the ends of the groove 46 and the side walls 50.
  • [0054]
    One of the key concepts in FIG. 3b is that the ductile hinge 44 has a constant or substantially constant width along at least a portion of its total length. In this configuration, there is no local minimum width along the ductile hinge axis, as there is with pairs of concave roots. There is therefore no point concentration of stresses and strains along the length of the ductile hinge beam during stent expansion. In particular, maximum tensile and compressive strains will be distributed evenly along the upper and lower surfaces of the hinge 44 during stent expansion. With the gross bend angle limited by mechanical stops, which are described below in detail, the maximum material strain (at the hinge surfaces) can therefore be reliably limited by adjusting the initial length of the ductile hinge over which the total elongation is distributed.
  • [0055]
    [0055]FIG. 3d shows a ductile hinge 60 in a cylindrical wire 62 for incorporating into a wire-form tissue-supporting device. The ductile hinge 60 is formed by a reduced diameter portion of the wire 62. Again, it is important that the ductile hinge have a substantially constant width over a portion of its length in order to provide strain control. Preferably, the ductile hinge is prismatic over a portion of its length. Maximum material strain can be varied by adjusting the hinge length. The ductile hinges of the present invention have a constant or substantially constant width over at least {fraction (1/3)} of the ductile hinge length, and preferably over at least {fraction (1/2)} of the ductile hinge length.
  • [0056]
    [0056]FIG. 3e shows an asymmetric ductile hinge 63 that produces different strain versus deflection-angle functions in expansion and compression. Each of the ductile hinges 64 is formed between a convex surface 68 and a concave surface 69. The ductile hinge 64 according to a preferred embodiment essentially takes the form of a small, prismatic curved beam having a substantially constant cross section. However, a thickness of the curved ductile hinge 64 may vary somewhat as long as the ductile hinge width remains constant along a portion of the hinge length. The width of the curved beam is measure along the radius of curvature of the beam. This small curved beam is oriented such that the smaller concave surface 69 is placed in tension in the device crimping direction, while the larger convex surface 68 of the ductile hinges is placed in tension in the device expansion direction. Again, there is no local minimum width of the ductile hinge 64 along the (curved) ductile hinge axis, and no concentration of material strain. During device expansion tensile strain will be distributed along the convex surface 68 of the hinge 64 and maximum expansion will be limited by the angle of the walls of the concave notch 69 which provide a geometric deflection limiting feature. Maximum tensile strain can therefore be reliably limited by adjusting the initial length of the convex arc shaped ductile hinge 64 over which the total elongation is distributed.
  • [0057]
    The ductile hinges illustrated in FIGS. 3a-e are examples of different structures that will function as a stress/strain concentrator. Many other stress/strain concentrator configurations may also be used as the ductile hinges in the present invention. The ductile hinges according to the present invention generally include an abrupt change in width of a strut that functions to concentrate stresses and strains in the narrower section of the strut. These ductile hinges also generally include features to limit mechanical deflection of attached struts and features to control material strain during large strut deflections. Although the ductile hinges have been illustrated in FIG. 2 as positioned at the ends of each of the axial slots 22, they may also be positioned at other locations in other designs without departing from the present invention.
  • [0058]
    An alternative embodiment of a tissue supporting device 80 is illustrated in FIG. 4a and in the enlarged side view of FIG. 4b. The tissue supporting device 80 includes a plurality of cylindrical tubes 82 connected by S-shaped bridging elements 84. The bridging elements 84 allow the tissue supporting device to bend axially when passing through the tortuous path of the vasculature to the deployment site and allow the device to bend when necessary to match the curvature of a lumen to be supported. The S-shaped bridging elements 84 provide improved axial flexibility over prior art devices due to the thickness of the elements in the radial direction which allows the width of the elements to be relatively small without sacrificing radial strength. For example, the width of the bridging elements 84 may be about 0.0012-0.0013 inches (0.0305-0.0330 mm). Each of the cylindrical tubes 82 has a plurality of axial slots 86 extending from an end surface of the cylindrical tube toward an opposite end surface. A plurality of axial struts 88 having ductile hinges 90 are formed between the axial slots 86. The ductile hinges 90 are formed by circumferential slots 92 formed at the interior ends of the axial slots 86 and opposed notches 94.
  • [0059]
    The notches 94 each have two opposed angled walls 96 which function as a stop to limit geometric deflection of the ductile hinge, and thus limit maximum device expansion. As the cylindrical tubes 82 are expanded and bending occurs at the ductile hinges 90, the angled side walls 96 of the notches 94 move toward each other. Once the opposite side walls 96 of a notch come into contact with each other, they resist further expansion of the particular ductile hinge causing further expansion to occur at other sections of the tissue supporting device. This geometric deflection limiting feature is particularly useful where uneven expansion is caused by either variations in the tissue supporting device 80 due to manufacturing tolerances or uneven balloon expansion.
  • [0060]
    The tissue supporting device 20, 80 according to the present invention may be formed of any ductile material, such as steel, gold, silver, tantalum, titanium, Nitinol, other shape memory alloys, other metals, or even some plastics. One preferred method for making the tissue supporting device 20, 80 involves forming a cylindrical tube and then laser cutting the slots 22, 26, 86, 92 and notches 94 into the tube. Alternatively, the tissue supporting device may be formed by electromachining, chemical etching followed by rolling and welding, or any other known method.
  • [0061]
    The design and analysis of stress/strain concentration for ductile hinges, and stress/strain concentration features in general, is complex. For example, the stress concentration factor for the simplified ductile hinge geometry of FIG. 3a can be calculated and is given by the following expression where D is the width of the struts 28, h is the height of the circular grooves 38, 40, and r is the radius of curvature of the grooves. For purposes of this example the ratio of h/r is taken to be 4. However, other ratios of h/r can also be implemented successfully. K = 4.935 - 7.586 ( 2 h D ) + 0.515 ( 2 h D ) 2 + 0.432 ( 2 h D ) 3
  • [0062]
    The stress concentration factors are generally useful only in the linear elastic range. Stress concentration patterns for a number of other geometries can be determined through photoelastic measurements and other experimental methods. Stent designs based on the use of stress/strain concentration features, or ductile hinges, generally involve more complex hinge geometries and operate in the non-linear elastic and plastic deformation regimes.
  • [0063]
    The general nature of the relationship among applied forces, material properties, and ductile hinge geometry can be more easily understood through analysis of an idealized hinge 66 as shown in FIGS. 5a-5 c. The hinge 66 is a simple beam of rectangular cross section having a width h, length L and thickness b. The idealized hinge 66 has elastic-ideally-plastic material properties which are characterized by the ideal stress/strain curve of FIG. 5d. It can be shown that the “plastic” or “ultimate bending moment” for such a beam is given by the expression: M p M u l t = δ y p b h 2 4
  • [0064]
    Where b corresponds to the cylindrical tube wall thickness, h is the circumferential width of the ductile hinge, and δyp is the yield stress of the hinge material. Assuming only that expansion pressure is proportional to the plastic moment, it can be seen that the required expansion pressure to expand the tissue supporting device increases linearly with wall thickness b and as the square of ductile hinge width h. It is thus possible to compensate for relatively large changes in wall thickness b with relatively small changes in hinge width h. While the above idealized case is only approximate, empirical measurements of expansion forces for different hinge widths in several different ductile hinge geometries have confirmed the general form of this relationship. Accordingly, for different ductile hinge geometries it is possible to increase the thickness of the tissue supporting device to achieve radiopacity while compensating for the increased thickness with a much smaller decrease in hinge width.
  • [0065]
    Ideally, the stent wall thickness b should be as thin as possible while still providing good visibility on a fluoroscope. For most stent materials, including stainless steel, this would suggest a thickness of about 0.005-0.007 inches (0.127-0.178 mm) or greater. The inclusion of ductile hinges in a stent design can lower expansion forces/pressures to very low levels for any material thickness of interest. Thus ductile hinges allow the construction of optimal wall thickness tissue supporting devices at expansion force levels significantly lower than current non-visible designs.
  • [0066]
    The expansion forces required to expand the tissue supporting device 20 according to the present invention from an initial condition illustrated in FIG. 2 to an expanded condition is between 1 and 5 atmospheres, preferably between 2 and 3 atmospheres. The expansion may be performed in a known manner, such as by inflation of a balloon or by a mandrel. The tissue supporting device 20 in the expanded condition has a diameter which is preferably up to three times the diameter of the device in the initial unexpanded condition.
  • [0067]
    Many tissue supporting devices fashioned from cylindrical tubes comprise networks of long, narrow, prismatic beams of essentially rectangular cross section as shown in FIG. 6. These beams which make up the known tissue supporting devices may be straight or curved, depending on the particular design. Known expandable tissue supporting devices have a typical wall thickness b of 0.0025 inches (0.0635 mm), and a typical strut width h of 0.005 to 0.006 inches (0.127-0.1524 mm). The ratio of b:h for most known designs is 1:2 or lower. As b decreases and as the beam length L increases, the beam is increasingly likely to respond to an applied bending moment M by buckling, and many designs of the prior art have displayed this behavior. This can be seen in the following expression for the “critical buckling moment” for the beam of FIG. 6. M c r i t = π b 3 h E G ( 1 - 0.63 b / h ) 6 L
  • [0068]
    Where:
  • [0069]
    E=Modulus of Elasticity
  • [0070]
    G=Shear Modulus
  • [0071]
    By contrast, in a ductile hinge based design according to the present invention, only the hinge itself deforms during expansion. The typical ductile hinge 32 is not a long narrow beam as are the struts in the known stents. Wall thickness of the present invention may be increased to 0.005 inches (0.127 mm) or greater, while hinge width is typically 0.002-0.003 inches (0.0508-0.0762 mm), preferably 0.0025 inches (0.0635 mm) or less. Typical hinge length, at 0.002 to 0.005 inches (0.0508-0.0127 mm), is more than an order of magnitude less than typical strut length. Thus, the ratio of b:h in a typical ductile hinge 32 is 2:1 or greater. This is an inherently stable ratio, meaning that the plastic moment for such a ductile hinge beam is much lower than the critical buckling moment Merit, and the ductile hinge beam deforms through normal strain-curvature. Ductile hinges 32 are thus not vulnerable to buckling when subjected to bending moments during expansion of the tissue supporting device 20.
  • [0072]
    To provide optimal recoil and crush-strength properties, it is desirable to design the ductile hinges so that relatively large strains, and thus large curvatures, are imparted to the hinge during expansion of the tissue supporting device. Curvature is defined as the reciprocal of the radius of curvature of the neutral axis of a beam in pure bending. A larger curvature during expansion results in the elastic curvature of the hinge being a small fraction of the total hinge curvature. Thus, the gross elastic recoil of the tissue supporting device is a small fraction of the total change in circumference. It is generally possible to do this because common stent materials, such as 316L Stainless Steel have very large elongations-to-failure (i.e., they are very ductile).
  • [0073]
    It is not practical to derive exact expressions for residual curvatures for complex hinge geometries and real materials (i.e., materials with non-idealized stress/strain curves). The general nature of residual curvatures and recoil of a ductile hinge may be understood by examining the moment-curvature relationship for the elastic-ideally-plastic rectangular hinge 66 shown in FIGS. 5a-c. It may be shown that the relationship between the applied moment and the resulting beam curvature is: M = M p [ 1 - 1 3 ( y o h / 2 ) 2 ] = 3 2 M y p [ 1 - 1 3 ( κ y p κ ) 2 ]
  • [0074]
    This function is plotted in FIG. 7. It may be seen in this plot that the applied moment M asymptotically approaches a limiting value Mp, called the plastic or ultimate moment. Beyond {fraction (11/12)} Mp large plastic deformations occur with little additional increase in applied moment. When the applied moment is removed, the beam rebounds elastically along a line such as a-b. Thus, the elastic portion of the total curvature approaches a limit of {fraction (3/2)} the curvature at the yield point. These relations may be expressed as follows: M p = 3 2 M y p κ r e b o u n d = 3 2 κ y p
  • [0075]
    Imparting additional curvature in the plastic zone cannot further increase the elastic curvature, but will decrease the ratio of elastic to plastic curvature. Thus, additional curvature or larger expansion of the tissue supporting device will reduce the percentage recoil of the overall stent structure.
  • [0076]
    As shown in FIG. 8, when a rigid strut 28 is linked to the ductile hinge 66 described above, the strut 28 forms an angle θ with the horizontal that is a function of hinge curvature. A change in hinge curvature results in a corresponding change in this angle θ. The angular elastic rebound of the hinge is the change in angle Δθ that results from the rebound in elastic curvature described above, and thus angular rebound also approaches a limiting value as plastic deformation proceeds. The following expression gives the limiting value of angular elastic rebound for the idealized hinge of FIG. 8. θ r e b o u n d = 3 ε y p L h
  • [0077]
    Where strain at the yield point is an independent material property (yield stress divided by elastic modulus); L is the length of the ductile hinge; and h is the width of the hinge. For non-idealized ductile hinges made of real materials, the constant 3 in the above expression is replaced by a slowly rising function of total strain, but the effect of geometry would remain the same. Specifically, the elastic rebound angle of a ductile hinge decreases as the hinge width h increases, and increases as the hinge length L increases. To minimize recoil, therefore, hinge width h should be increased and length L should be decreased.
  • [0078]
    Ductile hinge width h will generally be determined by expansion force criteria, so it is important to reduce hinge length to a practical minimum in order to minimize elastic rebound. Empirical data on recoil for ductile hinges of different lengths show significantly lower recoil for shorter hinge lengths, in good agreement with the above analysis.
  • [0079]
    The ductile hinges 32 of the tissue supporting device 20 provide a second important advantage in minimizing device recoil. The embodiment of FIG. 2 shows a network of struts joined together through ductile hinges to form a cylinder. In this design, the struts 28 are initially parallel to an axis of the device. As the device is expanded, curvature is imparted to the hinges 32, and the struts 28 assume an angle θ with respect to their original orientation, as shown in FIG. 8. The total circumferential expansion of the tissue supporting device structure is a function of hinge curvature (strut angle) and strut length. Moreover, the incremental contribution to stent expansion (or recoil) for an individual strut depends on the instantaneous strut angle. Specifically, for an incremental change in strut angle Δθ, the incremental change in circumference ΔC will depend on the strut length R and the cosine of the strut angle θ.
  • ΔC=RΔθ cos θ
  • [0080]
    Since elastic rebound of hinge curvature is nearly constant at any gross curvature, the net contribution to circumferential recoil ΔC is lower at higher strut angles θ. The final device circumference is usually specified as some fixed value, so decreasing overall strut length can increase the final strut angle θ. Total stent recoil can thus be minimized with ductile hinges by using shorter struts and higher hinge curvatures when expanded.
  • [0081]
    Empirical measurements have shown that tissue supporting device designs based on ductile hinges, such as the embodiment of FIG. 2, display superior resistance to compressive forces once expanded despite their very low expansion force. This asymmetry between compressive and expansion forces may be due to a combination of factors including the geometry of the ductile hinge, the increased wall thickness, and increased work hardening due to higher strain levels.
  • [0082]
    According to one example of the tissue supporting device of the invention, the device can be expanded by application of an internal pressure of about 2 atmospheres or less, and once expanded to a diameter between 2 and 3 times the initial diameter can withstand a compressive force of about 16 to 20 gm/mm or greater. Examples of typical compression force values for prior art devices are 3.8 to 4.0 gm/mm.
  • [0083]
    While both recoil and crush strength properties of tissue supporting devices can be improved by use of ductile hinges with large curvatures in the expanded configuration, care must be taken not to exceed an acceptable maximum strain level for the material being used. For the ductile hinge 44 of FIG. 3b, for example, it may be shown that the maximum material strain for a given bend angle is given by the expression: ɛ max = h L θ 2
  • [0084]
    Where εmax is maximum strain, h is ductile hinge width, L is ductile hinge length and θ is bend angle in radians. When strain, hinge width and bend angle are determined through other criteria, this expression can be evaluated to determine the correct ductile hinge length L.
  • [0085]
    For example, suppose the ductile hinge 44 of FIG. 3b was to be fabricated of 316L stainless steel with a maximum strain of 30%; ductile hinge width h is set at 0.0025 inch (0.0635 mm) by expansion force criteria; and the bend angle θ is mechanically limited to 0.5 radians (≅30%) at full stent expansion. Solving the above expression for L gives the required ductile hinge length of at least about 0.0033 inches (0.0838 mm).
  • [0086]
    Similar expressions may be developed to determine required lengths for more complicated ductile hinge geometries, such as shown in FIG. 3e. Typical values for the prismatic portions of these curved ductile hinges range from about 0.002 to about 0.0035 inches (0.051-0.089 mm) in hinge width and about 0.002 to about 0.006 inches (0.051-0.152 mm) in hinge length. The tissue supporting device design of FIGS. 4a and 4 b include a stop which limits the maximum geometric deflection at the ductile hinges by the design of the angled walls 96 of the notches 94.
  • [0087]
    In many designs of the prior art, circumferential expansion was accompanied by a significant contraction of the axial length of the stent which may be up to 15% of the initial device length. Excessive axial contraction can cause a number of problems in device deployment and performance including difficulty in proper placement and tissue damage. Designs based on ductile hinges 32 can minimize the axial contraction, or foreshortening, of a tissue supporting device during expansion as follows.
  • [0088]
    [0088]FIGS. 9a and 9 b illustrate an exaggerated ductile hinge 32 and shortened struts 28 in initial and expanded conditions. Each strut 28 is attached to two ductile hinges 32 at opposite ends. Each ductile hinge 32 has an instant center of rotation C1, C2 that is an effective pivot point for the attached strut 28. Initially, during expansion the pivot point C1 is displaced vertically by a distance d until C1 is positioned even with C2 as shown in FIG. 9b. When the array is expanded vertically, the axial struts 28 move in a circular arc with respect to the pivot points, as shown in FIG. 9b. It can be seen that the horizontal distance e between pivot points C1 and C2 actually increases initially, reaching a maximum emax when the two points are on the same horizontal axis as shown in FIG. 9b. As the vertical expansion continues, the device compresses axially back to its original length. Only when vertical expansion of the array continues beyond the point where the horizontal distance e between C1 and C2 is the same as the original horizontal distance e does the overall length of the array actually begin to contract. For the stent shown in FIG. 2, for example, approximately {fraction (1/3)} of the total circumferential expansion has been accomplished by the time the configuration of FIG. 9b is reached, and the stent exhibits very low axial contraction.
  • [0089]
    This ability to control axial contraction based on hinge and strut design provides great design flexibility when using ductile hinges. For example, a stent could be designed with zero axial contraction.
  • [0090]
    An alternative embodiment that illustrates the trade off between crush strength and axial contraction is shown in FIG. 10. FIG. 10 shows a portion of a tissue supporting device 70 having an array of struts 72 and ductile hinges 74 in the unexpanded state. The struts 72 are positioned initially at an angle θ1 with respect to a longitudinal axis X of the device. As the device is expanded radially from the unexpanded state illustrated in FIG. 10, the angle θ1 increases. In this case the device contracts axially from the onset of vertical expansion throughout the expansion. Once the device has been completely expanded the final angle θ1 made by the strut 72 with the horizontal will be much greater than the angle θ in the device of FIGS. 8a and 8 b. As shown previously, a higher final strut angle θ1, can significantly increase crush strength and decrease circumferential recoil of the stent structure. However, there is a trade off between increased crush strength and increase in axial contraction.
  • [0091]
    According to one example of the present invention, the struts 72 are positioned initially at an angle of about 0 to 45 with respect to a longitudinal axis of the device. As the device is expanded radially from the unexpanded state illustrated in FIG. 10a, the strut angle increases to about 20 to 80.
  • [0092]
    According to one alternative embodiment of the present invention, the expandable tissue supporting device can also be used as a delivery device for certain beneficial agents including drugs, chemotherapy, or other agents. Due to the structure of the tissue supporting device incorporating ductile hinges, the widths of the struts can be substantially larger than the struts of the prior art devices. The struts due to their large size can be used for beneficial agent delivery by providing beneficial agent on the struts or within the struts. Examples of beneficial agent delivery mechanisms include coatings on the struts, such as polymer coatings containing beneficial agents, laser drilled holes in the struts containing beneficial agent, and the like.
  • [0093]
    While the invention has been described in detail with reference to the preferred embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made and equivalents employed, without departing from the present invention.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3657744 *May 8, 1970Apr 25, 1972Univ MinnesotaMethod for fixing prosthetic implants in a living body
US4531936 *Jan 12, 1983Jul 30, 1985Gordon Robert TDevice and method for the selective delivery of drugs to the myocardium
US4580568 *Oct 1, 1984Apr 8, 1986Cook, IncorporatedPercutaneous endovascular stent and method for insertion thereof
US4650466 *Nov 1, 1985Mar 17, 1987Angiobrade PartnersAngioplasty device
US4733665 *Nov 7, 1985Mar 29, 1988Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4739762 *Nov 3, 1986Apr 26, 1988Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882 *Mar 13, 1987Jan 31, 1989Cook IncorporatedEndovascular stent and delivery system
US4824436 *Apr 21, 1987Apr 25, 1989Harvey WolinskyMethod for the prevention of restenosis
US4834755 *Mar 4, 1985May 30, 1989Pfizer Hospital Products Group, Inc.Triaxially-braided fabric prosthesis
US4989601 *Sep 22, 1988Feb 5, 1991Medical Engineering & Development Institute, Inc.Method, apparatus, and substance for treating tissue having neoplastic cells
US4990155 *May 19, 1989Feb 5, 1991Wilkoff Howard MSurgical stent method and apparatus
US4994071 *May 22, 1989Feb 19, 1991Cordis CorporationBifurcating stent apparatus and method
US5019090 *Sep 1, 1988May 28, 1991Corvita CorporationRadially expandable endoprosthesis and the like
US5078726 *Apr 9, 1990Jan 7, 1992Kreamer Jeffry WGraft stent and method of repairing blood vessels
US5092841 *May 17, 1990Mar 3, 1992Wayne State UniversityMethod for treating an arterial wall injured during angioplasty
US5102417 *Mar 28, 1988Apr 7, 1992Expandable Grafts PartnershipExpandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US5176617 *Oct 21, 1991Jan 5, 1993Medical Innovative Technologies R & D Limited PartnershipUse of a stent with the capability to inhibit malignant growth in a vessel such as a biliary duct
US5195984 *Feb 19, 1991Mar 23, 1993Expandable Grafts PartnershipExpandable intraluminal graft
US5197978 *Apr 26, 1991Mar 30, 1993Advanced Coronary Technology, Inc.Removable heat-recoverable tissue supporting device
US5213580 *Mar 25, 1992May 25, 1993Endoluminal Therapeutics, Inc.Biodegradable polymeric endoluminal sealing process
US5234456 *May 7, 1992Aug 10, 1993Pfizer Hospital Products Group, Inc.Hydrophilic stent
US5286254 *Aug 28, 1992Feb 15, 1994Cortrak Medical, Inc.Drug delivery apparatus and method
US5292512 *Dec 20, 1989Mar 8, 1994Centre Internationale De Recherches Dermatologiques (C.I.R.D.)Cosmetic or pharmaceutical composition containing microspheres of polymers or of fatty substances filled with at least one active product
US5304121 *Nov 22, 1991Apr 19, 1994Boston Scientific CorporationDrug delivery system making use of a hydrogel polymer coating
US5314688 *Feb 9, 1993May 24, 1994Eli Lilly And CompanyLocal delivery of dipyridamole for the treatment of proliferative diseases
US5342348 *Dec 4, 1992Aug 30, 1994Kaplan Aaron VMethod and device for treating and enlarging body lumens
US5342621 *Sep 15, 1992Aug 30, 1994Advanced Cardiovascular Systems, Inc.Antithrombogenic surface
US5380299 *Aug 30, 1993Jan 10, 1995Med Institute, Inc.Thrombolytic treated intravascular medical device
US5383892 *Nov 6, 1992Jan 24, 1995Meadox FranceStent for transluminal implantation
US5383928 *Aug 19, 1993Jan 24, 1995Emory UniversityStent sheath for local drug delivery
US5403858 *Jul 3, 1992Apr 4, 1995Rhone-Poulenc Rorer, S.A.New compositions containing taxane derivatives
US5407683 *Oct 1, 1992Apr 18, 1995Research Corporation Technologies, Inc.Pharmaceutical solutions and emulsions containing taxol
US5415869 *Nov 12, 1993May 16, 1995The Research Foundation Of State University Of New YorkTaxol formulation
US5419760 *Oct 11, 1994May 30, 1995Pdt Systems, Inc.Medicament dispensing stent for prevention of restenosis of a blood vessel
US5439446 *Jun 30, 1994Aug 8, 1995Boston Scientific CorporationStent and therapeutic delivery system
US5499373 *Nov 9, 1994Mar 12, 1996Sony CorporationApparatus and methods for designing, analyzing or simulating signal processing functions
US5523092 *Jan 28, 1994Jun 4, 1996Emory UniversityDevice for local drug delivery and methods for using the same
US5593434 *Jun 7, 1995Jan 14, 1997Advanced Cardiovascular Systems, Inc.Stent capable of attachment within a body lumen
US5607442 *Nov 13, 1995Mar 4, 1997Isostent, Inc.Stent with improved radiopacity and appearance characteristics
US5616608 *Apr 18, 1996Apr 1, 1997The United States Of America As Represented By The Department Of Health And Human ServicesMethod of treating atherosclerosis or restenosis using microtubule stabilizing agent
US5617878 *May 31, 1996Apr 8, 1997Taheri; Syde A.Stent and method for treatment of aortic occlusive disease
US5618299 *Aug 8, 1995Apr 8, 1997Advanced Cardiovascular Systems, Inc.Ratcheting stent
US5624411 *Jun 7, 1995Apr 29, 1997Medtronic, Inc.Intravascular stent and method
US5628787 *Jun 7, 1995May 13, 1997Schneider (Usa) Inc.Clad composite stent
US5643314 *Nov 13, 1995Jul 1, 1997Navius CorporationSelf-expanding stent
US5707385 *Nov 16, 1994Jan 13, 1998Advanced Cardiovascular Systems, Inc.Drug loaded elastic membrane and method for delivery
US5713949 *Aug 6, 1996Feb 3, 1998Jayaraman; SwaminathanMicroporous covered stents and method of coating
US5716981 *Jun 7, 1995Feb 10, 1998Angiogenesis Technologies, Inc.Anti-angiogenic compositions and methods of use
US5725548 *Apr 8, 1996Mar 10, 1998Iowa India Investments Company LimitedSelf-locking stent and method for its production
US5725549 *Sep 12, 1996Mar 10, 1998Advanced Cardiovascular Systems, Inc.Coiled stent with locking ends
US5733330 *Jan 13, 1997Mar 31, 1998Advanced Cardiovascular Systems, Inc.Balloon-expandable, crush-resistant locking stent
US5733925 *Oct 28, 1996Mar 31, 1998Neorx CorporationTherapeutic inhibitor of vascular smooth muscle cells
US5741293 *Nov 28, 1995Apr 21, 1998Wijay; BandulaLocking stent
US5759192 *Jan 15, 1997Jun 2, 1998Advanced Cardiovascular Systems, Inc.Method and apparatus for direct laser cutting of metal stents
US5766239 *Oct 3, 1997Jun 16, 1998Advanced Cardiovascular Systems, Inc.Balloon-expandable, crush resistant locking stent and method of loading the same
US5769883 *Nov 21, 1995Jun 23, 1998Scimed Life Systems, Inc.Biodegradable drug delivery vascular stent
US5776181 *Jul 25, 1996Jul 7, 1998Medstent Inc.Expandable stent
US5855600 *Aug 1, 1997Jan 5, 1999Inflow Dynamics Inc.Flexible implantable stent with composite design
US5868781 *Oct 22, 1996Feb 9, 1999Scimed Life Systems, Inc.Locking stent
US5873904 *Feb 24, 1997Feb 23, 1999Cook IncorporatedSilver implantable medical device
US5876419 *Oct 15, 1997Mar 2, 1999Navius CorporationStent and method for making a stent
US5882335 *Feb 29, 1996Mar 16, 1999Cordis CorporationRetrievable drug delivery stent
US5886026 *Jun 7, 1995Mar 23, 1999Angiotech Pharmaceuticals Inc.Anti-angiogenic compositions and methods of use
US5922020 *Aug 2, 1996Jul 13, 1999Localmed, Inc.Tubular prosthesis having improved expansion and imaging characteristics
US5922021 *Apr 25, 1997Jul 13, 1999Jang; G. DavidIntravascular stent
US6017363 *Feb 24, 1998Jan 25, 2000Cordis CorporationBifurcated axially flexible stent
US6019789 *Apr 1, 1998Feb 1, 2000Quanam Medical CorporationExpandable unit cell and intraluminal stent
US6022371 *Jul 21, 1998Feb 8, 2000Scimed Life Systems, Inc.Locking stent
US6030414 *Nov 13, 1997Feb 29, 2000Taheri; Syde A.Variable stent and method for treatment of arterial disease
US6042606 *Sep 29, 1997Mar 28, 2000Cook IncorporatedRadially expandable non-axially contracting surgical stent
US6056722 *Sep 18, 1997May 2, 2000Iowa-India Investments Company Limited Of DouglasDelivery mechanism for balloons, drugs, stents and other physical/mechanical agents and methods of use
US6063101 *Nov 20, 1998May 16, 2000Precision Vascular Systems, Inc.Stent apparatus and method
US6071305 *Nov 24, 1997Jun 6, 2000Alza CorporationDirectional drug delivery stent and method of use
US6083258 *May 28, 1998Jul 4, 2000Yadav; Jay S.Locking stent
US6087479 *Jun 2, 1995Jul 11, 2000Nitromed, Inc.Localized use of nitric oxide-adducts to prevent internal tissue damage
US6174326 *Sep 23, 1997Jan 16, 2001Terumo Kabushiki KaishaRadiopaque, antithrombogenic stent and method for its production
US6193746 *Sep 4, 1996Feb 27, 2001Ernst Peter StreckerEndoprosthesis that can be percutaneously implanted in the patient's body
US6206914 *Aug 31, 1998Mar 27, 2001Medtronic, Inc.Implantable system with drug-eluting cells for on-demand local drug delivery
US6206915 *Sep 29, 1998Mar 27, 2001Medtronic Ave, Inc.Drug storing and metering stent
US6206916 *Jul 29, 1999Mar 27, 2001Joseph G. FurstCoated intraluminal graft
US6231600 *May 26, 1999May 15, 2001Scimed Life Systems, Inc.Stents with hybrid coating for medical devices
US6240616 *Apr 15, 1997Jun 5, 2001Advanced Cardiovascular Systems, Inc.Method of manufacturing a medicated porous metal prosthesis
US6241762 *Oct 29, 1998Jun 5, 2001Conor Medsystems, Inc.Expandable medical device with ductile hinges
US6245101 *May 3, 1999Jun 12, 2001William J. DraslerIntravascular hinge stent
US6249952 *Mar 8, 1999Jun 26, 2001Scimed Life Systems, Inc.Method for manufacturing an expandable stent
US6395326 *May 31, 2000May 28, 2002Advanced Cardiovascular Systems, Inc.Apparatus and method for depositing a coating onto a surface of a prosthesis
US6506411 *Apr 19, 1999Jan 14, 2003Angiotech Pharmaceuticals, Inc.Anti-angiogenic compositions and methods of use
US6506437 *Oct 17, 2000Jan 14, 2003Advanced Cardiovascular Systems, Inc.Methods of coating an implantable device having depots formed in a surface thereof
US6544544 *Aug 8, 2001Apr 8, 2003Angiotech Pharmaceuticals, Inc.Anti-angiogenic compositions and methods of use
US6558733 *Oct 26, 2000May 6, 2003Advanced Cardiovascular Systems, Inc.Method for etching a micropatterned microdepot prosthesis
US20010000802 *Dec 20, 2000May 3, 2001Medtronic, Inc.Implantable system with drug-eluting cells for on-demand local drug delivery
US20020002400 *Aug 8, 2001Jan 3, 2002Drasler William J.Intravascular hinge stent
US20020005206 *May 7, 2001Jan 17, 2002Robert FaloticoAntiproliferative drug and delivery device
US20020007209 *Mar 6, 2001Jan 17, 2002Scheerder Ivan DeIntraluminar perforated radially expandable drug delivery prosthesis and a method for the production thereof
US20020022876 *May 25, 2001Feb 21, 2002Jacob RichterLongitudinally flexible stent
US20020038145 *Jun 4, 2001Mar 28, 2002Jang G. DavidIntravascular stent with increasing coating retaining capacity
US20020072511 *Aug 30, 2001Jun 13, 2002Gishel NewApparatus and method for delivering compounds to a living organism
US20020082679 *Nov 1, 2001Jun 27, 2002Avantec Vascular CorporationDelivery or therapeutic capable agents
US20020094985 *Jan 18, 2001Jul 18, 2002Herrmann Robert A.Differential delivery of nitric oxide
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7179289Jun 7, 2004Feb 20, 2007Conor Medsystems, Inc.Expandable medical device for delivery of beneficial agent
US7344514Aug 17, 2004Mar 18, 2008Innovational Holdings, LlcExpandable medical device delivery system and method
US7655030Apr 29, 2004Feb 2, 2010Boston Scientific Scimed, Inc.Catheter balloon systems and methods
US7658758Feb 9, 2010Innovational Holdings, LlcMethod and apparatus for loading a beneficial agent into an expandable medical device
US7678142Aug 4, 2004Mar 16, 2010Boston Scientific Scimed, Inc.Extendible stent apparatus
US7758636Jul 20, 2010Innovational Holdings LlcExpandable medical device with openings for delivery of multiple beneficial agents
US7766955May 19, 2003Aug 3, 2010Boston Scientific Scimed, Inc.Extendible stent apparatus
US7771462Sep 15, 2000Aug 10, 2010Boston Scientific Scimed, Inc.Catheter with side sheath and methods
US7842083Nov 30, 2010Innovational Holdings, Llc.Expandable medical device with improved spatial distribution
US7850725Jun 15, 2006Dec 14, 2010Boston Scientific Scimed, Inc.Extendible stent apparatus
US7850727Dec 14, 2010Innovational Holdings, LlcExpandable medical device for delivery of beneficial agent
US7892279Feb 22, 2011Boston Scientific Scimed, Inc.Extendible stent apparatus
US7931683Jul 27, 2007Apr 26, 2011Boston Scientific Scimed, Inc.Articles having ceramic coated surfaces
US7938855May 10, 2011Boston Scientific Scimed, Inc.Deformable underlayer for stent
US7942926Jul 11, 2007May 17, 2011Boston Scientific Scimed, Inc.Endoprosthesis coating
US7976915Jul 12, 2011Boston Scientific Scimed, Inc.Endoprosthesis with select ceramic morphology
US7981150Jul 19, 2011Boston Scientific Scimed, Inc.Endoprosthesis with coatings
US7985252Jul 30, 2008Jul 26, 2011Boston Scientific Scimed, Inc.Bioerodible endoprosthesis
US7998192Aug 16, 2011Boston Scientific Scimed, Inc.Endoprostheses
US8002821Aug 23, 2011Boston Scientific Scimed, Inc.Bioerodible metallic ENDOPROSTHESES
US8002823Jul 11, 2007Aug 23, 2011Boston Scientific Scimed, Inc.Endoprosthesis coating
US8029554Nov 2, 2007Oct 4, 2011Boston Scientific Scimed, Inc.Stent with embedded material
US8048150Apr 12, 2006Nov 1, 2011Boston Scientific Scimed, Inc.Endoprosthesis having a fiber meshwork disposed thereon
US8052743Aug 2, 2007Nov 8, 2011Boston Scientific Scimed, Inc.Endoprosthesis with three-dimensional disintegration control
US8052744Sep 13, 2007Nov 8, 2011Boston Scientific Scimed, Inc.Medical devices and methods of making the same
US8052745Nov 8, 2011Boston Scientific Scimed, Inc.Endoprosthesis
US8057534Sep 14, 2007Nov 15, 2011Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8066763May 11, 2010Nov 29, 2011Boston Scientific Scimed, Inc.Drug-releasing stent with ceramic-containing layer
US8067054Nov 29, 2011Boston Scientific Scimed, Inc.Stents with ceramic drug reservoir layer and methods of making and using the same
US8070797Dec 6, 2011Boston Scientific Scimed, Inc.Medical device with a porous surface for delivery of a therapeutic agent
US8071156Mar 4, 2009Dec 6, 2011Boston Scientific Scimed, Inc.Endoprostheses
US8080055Dec 20, 2011Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8089029Feb 1, 2006Jan 3, 2012Boston Scientific Scimed, Inc.Bioabsorbable metal medical device and method of manufacture
US8128689Sep 14, 2007Mar 6, 2012Boston Scientific Scimed, Inc.Bioerodible endoprosthesis with biostable inorganic layers
US8187321Sep 7, 2005May 29, 2012Innovational Holdings, LlcExpandable medical device for delivery of beneficial agent
US8187620May 29, 2012Boston Scientific Scimed, Inc.Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8211167Jan 23, 2004Jul 3, 2012Boston Scientific Scimed, Inc.Method of using a catheter with attached flexible side sheath
US8216632Jul 10, 2012Boston Scientific Scimed, Inc.Endoprosthesis coating
US8221822Jul 30, 2008Jul 17, 2012Boston Scientific Scimed, Inc.Medical device coating by laser cladding
US8231980Jul 31, 2012Boston Scientific Scimed, Inc.Medical implants including iridium oxide
US8236046Jun 10, 2008Aug 7, 2012Boston Scientific Scimed, Inc.Bioerodible endoprosthesis
US8241349Feb 3, 2011Aug 14, 2012Boston Scientific Scimed, Inc.Extendible stent apparatus
US8267992Sep 18, 2012Boston Scientific Scimed, Inc.Self-buffering medical implants
US8287937Apr 24, 2009Oct 16, 2012Boston Scientific Scimed, Inc.Endoprosthese
US8298280Oct 30, 2012Boston Scientific Scimed, Inc.Stent with protruding branch portion for bifurcated vessels
US8303643Nov 6, 2012Remon Medical Technologies Ltd.Method and device for electrochemical formation of therapeutic species in vivo
US8349390Jan 8, 2013Conor Medsystems, Inc.Method and apparatus for loading a beneficial agent into an expandable medical device
US8353949Sep 10, 2007Jan 15, 2013Boston Scientific Scimed, Inc.Medical devices with drug-eluting coating
US8377108Feb 19, 2013Boston Scientific Scimed, Inc.Staggered two balloon bifurcation catheter assembly and methods
US8382824Oct 3, 2008Feb 26, 2013Boston Scientific Scimed, Inc.Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides
US8431149Apr 30, 2013Boston Scientific Scimed, Inc.Coated medical devices for abluminal drug delivery
US8449603May 28, 2013Boston Scientific Scimed, Inc.Endoprosthesis coating
US8449901Mar 7, 2006May 28, 2013Innovational Holdings, LlcImplantable medical device with beneficial agent concentration gradient
US8486134Aug 1, 2007Jul 16, 2013Boston Scientific Scimed, Inc.Bifurcation treatment system and methods
US8574615May 25, 2010Nov 5, 2013Boston Scientific Scimed, Inc.Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8617231Sep 25, 2003Dec 31, 2013Boston Scientific Scimed, Inc.Dual guidewire exchange catheter system
US8668732Mar 22, 2011Mar 11, 2014Boston Scientific Scimed, Inc.Surface treated bioerodible metal endoprostheses
US8702779Jan 11, 2008Apr 22, 2014Boston Scientific Scimed, Inc.Catheter balloon systems and methods
US8715339Nov 21, 2011May 6, 2014Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8747456Dec 31, 2008Jun 10, 2014Boston Scientific Scimed, Inc.Bifurcation stent delivery system and methods
US8771334Dec 15, 2009Jul 8, 2014Boston Scientific Scimed, Inc.Catheter balloon systems and methods
US8771342Sep 8, 2009Jul 8, 2014Boston Scientific Scimed, Inc.Methods for deploying stents in bifurcations
US8771343Jun 15, 2007Jul 8, 2014Boston Scientific Scimed, Inc.Medical devices with selective titanium oxide coatings
US8808726Sep 14, 2007Aug 19, 2014Boston Scientific Scimed. Inc.Bioerodible endoprostheses and methods of making the same
US8815273Jul 27, 2007Aug 26, 2014Boston Scientific Scimed, Inc.Drug eluting medical devices having porous layers
US8815275Jun 28, 2006Aug 26, 2014Boston Scientific Scimed, Inc.Coatings for medical devices comprising a therapeutic agent and a metallic material
US8821561Feb 21, 2007Sep 2, 2014Boston Scientific Scimed, Inc.Marker arrangement for bifurcation catheter
US8827954Jun 5, 2009Sep 9, 2014Boston Scientific Scimed, Inc.Deflatable bifurcated device
US8840660Jan 5, 2006Sep 23, 2014Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US8852268 *Sep 16, 2009Oct 7, 2014Bentley Surgical GmbhStent having expandable elements
US8894900Oct 7, 2008Nov 25, 2014Advanced Cardiovascular Systems Inc.Stent with flexible sections in high strain regions
US8900292Oct 6, 2009Dec 2, 2014Boston Scientific Scimed, Inc.Coating for medical device having increased surface area
US8920491Apr 17, 2009Dec 30, 2014Boston Scientific Scimed, Inc.Medical devices having a coating of inorganic material
US8926689 *Jun 20, 2008Jan 6, 2015C. R. Bard, Inc.Flexible stent with hinged connectors
US8932346Apr 23, 2009Jan 13, 2015Boston Scientific Scimed, Inc.Medical devices having inorganic particle layers
US8936567Jun 5, 2009Jan 20, 2015Boston Scientific Scimed, Inc.Balloon bifurcated lumen treatment
US9254202Jan 8, 2013Feb 9, 2016Innovational Holdings LlcMethod and apparatus for loading a beneficial agent into an expandable medical device
US9284409Jul 17, 2008Mar 15, 2016Boston Scientific Scimed, Inc.Endoprosthesis having a non-fouling surface
US20020116047 *Jan 18, 2002Aug 22, 2002Vardi Gil M.Extendible stent apparatus and method for deploying the same
US20040015227 *May 19, 2003Jan 22, 2004Gil VardiExtendible stent apparatus
US20040127977 *Sep 22, 2003Jul 1, 2004Conor Medsystems, Inc.Expandable medical device with openings for delivery of multiple beneficial agents
US20040133268 *Oct 14, 2003Jul 8, 2004Advanced Stent Technologies, Inc.Extendible stent apparatus
US20040138737 *Aug 21, 2003Jul 15, 2004Advanced Stent Technologies, Inc.Stent with protruding branch portion for bifurcated vessels
US20040148006 *Jan 16, 2004Jul 29, 2004Davidson Charles JStent range transducers and methods of use
US20040202692 *Mar 26, 2004Oct 14, 2004Conor Medsystems, Inc.Implantable medical device and method for in situ selective modulation of agent delivery
US20040225350 *Jun 7, 2004Nov 11, 2004Shanley John F.Expandable medical device for delivery of beneficial agent
US20040238978 *Jun 18, 2004Dec 2, 2004Diaz Stephen HunterMethod and apparatus for loading a benefical agent into an expandable medical device
US20050010278 *Aug 4, 2004Jan 13, 2005Advanced Stent Technologies, Inc.Extendible stent apparatus
US20050058684 *Oct 28, 2004Mar 17, 2005Shanley John F.Therapeutic agent delivery device with controlled therapeutic agent release rates
US20050060027 *Jul 19, 2004Mar 17, 2005Advanced Stent Technologies, Inc.Catheter balloon systems and methods
US20050065596 *Jul 18, 2003Mar 24, 2005Xufan TsengStents capable of controllably releasing histone deacetylase inhibitors
US20050100577 *Apr 22, 2004May 12, 2005Parker Theodore L.Expandable medical device with beneficial agent matrix formed by a multi solvent system
US20050102019 *Nov 10, 2004May 12, 2005Advanced Stent Technologies, Inc.Catheter balloon systems and methods
US20050102023 *Dec 14, 2004May 12, 2005Amnon YadinStent with protruding branch portion for bifurcated vessels
US20050182390 *Feb 11, 2005Aug 18, 2005Conor Medsystems, Inc.Implantable drug delivery device including wire filaments
US20050203608 *Apr 26, 2005Sep 15, 2005Conor Medsystems, Inc.Expandable medical device for delivery of beneficial agent
US20050234544 *Jun 22, 2005Oct 20, 2005Conor Medsystems, Inc.Expandable medical device with openings for delivery of multiple beneficial agents
US20050261760 *May 12, 2005Nov 24, 2005Jan WeberMedical devices and methods of making the same
US20060008503 *Sep 13, 2005Jan 12, 2006Conor Medsystems, Inc.Therapeutic agent delivery device with controlled therapeutic agent release rates
US20060009838 *Sep 7, 2005Jan 12, 2006Conor Medsystems, Inc.Expandable medical device for delivery of beneficial agent
US20060030929 *Aug 9, 2004Feb 9, 2006Scimed Life Systems, Inc.Flap-cover aneurysm stent
US20060064157 *Nov 14, 2005Mar 23, 2006Conor Medsystems, Inc.Expandable medical device for delivery of beneficial agent
US20060079956 *Aug 10, 2005Apr 13, 2006Conor Medsystems, Inc.Bifurcation stent with crushable end and method for delivery of a stent to a bifurcation
US20060085061 *Nov 4, 2005Apr 20, 2006Vardi Gil MExtendible stent apparatus and method for deploying the same
US20060096660 *Oct 18, 2005May 11, 2006Conor Medsystems, Inc.Method and apparatus for loading a beneficial agent into an expandable medical device
US20060122697 *Mar 14, 2005Jun 8, 2006Conor Medsystems, Inc.Expandable medical device with openings for delivery of multiple beneficial agents
US20060147489 *Mar 7, 2006Jul 6, 2006Conor Medsystems, Inc.Implantable medical device with beneficial agent concentration gradient
US20060149354 *Feb 27, 2006Jul 6, 2006Conor Medsystems, Inc.Expandable medical device with improved spatial distribution
US20060178735 *Mar 28, 2006Aug 10, 2006Conor Medsystems, Inc.Expandable medical device and method for treating chronic total occlusions with local delivery of an angiogenic factor
US20060271170 *May 31, 2005Nov 30, 2006Gale David CStent with flexible sections in high strain regions
US20070038176 *Jul 5, 2005Feb 15, 2007Jan WeberMedical devices with machined layers for controlled communications with underlying regions
US20070082120 *Mar 2, 2005Apr 12, 2007Conor Medsystems, Inc.Method and apparatus for loading a beneficial agent into an expandable medical device
US20070156231 *Jan 5, 2006Jul 5, 2007Jan WeberBioerodible endoprostheses and methods of making the same
US20070178129 *Feb 1, 2006Aug 2, 2007Boston Scientific Scimed, Inc.Bioabsorbable metal medical device and method of manufacture
US20070203562 *Feb 21, 2007Aug 30, 2007Andrzej MalewiczMarker arrangement for bifurcation catheter
US20070224116 *Mar 27, 2006Sep 27, 2007Chandru ChandrasekaranMedical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US20070224244 *Mar 22, 2006Sep 27, 2007Jan WeberCorrosion resistant coatings for biodegradable metallic implants
US20070244569 *Apr 12, 2006Oct 18, 2007Jan WeberEndoprosthesis having a fiber meshwork disposed thereon
US20070264303 *May 12, 2006Nov 15, 2007Liliana AtanasoskaCoating for medical devices comprising an inorganic or ceramic oxide and a therapeutic agent
US20080004691 *Jun 15, 2007Jan 3, 2008Boston Scientific Scimed, Inc.Medical devices with selective coating
US20080071350 *Sep 13, 2007Mar 20, 2008Boston Scientific Scimed, Inc.Endoprostheses
US20080071357 *Aug 15, 2007Mar 20, 2008Girton Timothy SControlling biodegradation of a medical instrument
US20080086195 *Sep 18, 2007Apr 10, 2008Boston Scientific Scimed, Inc.Polymer-Free Coatings For Medical Devices Formed By Plasma Electrolytic Deposition
US20080109060 *Jan 11, 2008May 8, 2008Advanced Stent Technologies, Inc.Catheter balloon systems and methods
US20080109072 *Sep 13, 2007May 8, 2008Boston Scientific Scimed, Inc.Medical devices and methods of making the same
US20080140182 *Apr 24, 2007Jun 12, 2008Patricia SchellerComposite endoluminal prostheses for treating vulnerable plaque
US20080161906 *Dec 27, 2007Jul 3, 2008Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US20080183277 *Sep 14, 2007Jul 31, 2008Boston Scientific Scimed, Inc.Bioerodible endoprostheses and methods of making the same
US20080255581 *Jun 17, 2008Oct 16, 2008Boston Scientific Scimed, Inc.Short sleeve stent delivery catheter and methods
US20080294246 *May 23, 2007Nov 27, 2008Boston Scientific Scimed, Inc.Endoprosthesis with Select Ceramic Morphology
US20090018639 *Jul 11, 2007Jan 15, 2009Boston Scientific Scimed, Inc.Endoprosthesis coating
US20090029077 *Jul 27, 2007Jan 29, 2009Boston Scientific Scimed, Inc.Drug eluting medical devices having porous layers
US20090035448 *Jul 30, 2008Feb 5, 2009Boston Scientific Scimed, Inc.Medical device coating by laser cladding
US20090036972 *Oct 7, 2008Feb 5, 2009Advanced Cardiovascular Systems Inc.Stent With Flexible Sections In High Strain Regions
US20090118809 *Nov 2, 2007May 7, 2009Torsten ScheuermannEndoprosthesis with porous reservoir and non-polymer diffusion layer
US20090118813 *Nov 2, 2007May 7, 2009Torsten ScheuermannNano-patterned implant surfaces
US20090118822 *Nov 2, 2007May 7, 2009Holman Thomas JStent with embedded material
US20090143855 *Nov 29, 2007Jun 4, 2009Boston Scientific Scimed, Inc.Medical Device Including Drug-Loaded Fibers
US20090171430 *Dec 31, 2008Jul 2, 2009Boston Scientific Scimed, Inc.Bifurcation stent delivery system and methods
US20090240321 *May 26, 2009Sep 24, 2009Boston Scientific Scimed, Inc.Extendible Stent Apparatus
US20090281613 *May 9, 2008Nov 12, 2009Boston Scientific Scimed, Inc.Endoprostheses
US20090326634 *Sep 8, 2009Dec 31, 2009Boston Scientific Scimed, Inc.Methods for deploying stents in bifurcations
US20100004733 *Jan 7, 2010Boston Scientific Scimed, Inc.Implants Including Fractal Structures
US20100008970 *Jan 14, 2010Boston Scientific Scimed, Inc.Drug-Eluting Endoprosthesis
US20100030326 *Jul 30, 2008Feb 4, 2010Boston Scientific Scimed, Inc.Bioerodible Endoprosthesis
US20100087910 *Apr 8, 2010Jan WeberMedical implant
US20100114018 *Jun 5, 2009May 6, 2010Boston Scientific Scimed, Inc.Balloon bifurcated lumen treatment
US20100137977 *Oct 6, 2009Jun 3, 2010Boston Scientific Scimed, Inc.Coating for Medical Device Having Increased Surface Area
US20100137978 *Dec 3, 2009Jun 3, 2010Boston Scientific Scimed, Inc.Medical Implants Including Iridium Oxide
US20100222873 *Sep 2, 2010Boston Scientific Scimed, Inc.Self-Buffering Medical Implants
US20100228341 *Sep 9, 2010Boston Scientific Scimed, Inc.Endoprostheses
US20100233238 *May 25, 2010Sep 16, 2010Boston Scientific Scimed, Inc.Medical Devices Having Nanoporous Coatings for Controlled Therapeutic Agent Delivery
US20100272882 *Oct 28, 2010Boston Scientific Scimed, Inc.Endoprosthese
US20100274352 *Apr 24, 2009Oct 28, 2010Boston Scientific Scrimed, Inc.Endoprosthesis with Selective Drug Coatings
US20100280612 *Nov 4, 2010Boston Scientific Scimed, Inc.Medical Devices Having Vapor Deposited Nanoporous Coatings For Controlled Therapeutic Agent Delivery
US20100286763 *May 11, 2010Nov 11, 2010Boston Scientific Scimed, Inc.Drug-releasing stent with ceramic-containing layer
US20100324658 *Jun 20, 2008Dec 23, 2010C.R. Bard, Inc.Flexible stent with hinged connectors
US20110022158 *Jul 22, 2009Jan 27, 2011Boston Scientific Scimed, Inc.Bioerodible Medical Implants
US20110189377 *Aug 4, 2011Boston Scientific Scimed, Inc.Coating for Medical Devices Comprising An Inorganic or Ceramic Oxide and a Therapeutic Agent
US20110238151 *Sep 29, 2011Boston Scientific Scimed, Inc.Surface treated bioerodible metal endoprostheses
US20120158125 *Sep 16, 2009Jun 21, 2012Milisav ObradovicStent having expandable elements
WO2007117726A2 *Jan 9, 2007Oct 18, 2007Medtronic Vascular, Inc.Hinged stent
WO2007117726A3 *Jan 9, 2007Jan 24, 2008Justin GoshgarianHinged stent
Classifications
U.S. Classification623/1.15
International ClassificationA61F2/82, A61F2/84, A61F2/00, A61F2/06, A61F2/90
Cooperative ClassificationA61F2250/0036, A61F2250/0068, A61F2/91, A61F2002/91558, A61F2/915, A61F2250/0018, A61F2250/0029, A61F2002/91541
European ClassificationA61F2/915, A61F2/91
Legal Events
DateCodeEventDescription
May 8, 2007ASAssignment
Owner name: INNOVATIONAL HOLDINGS LLC, NEW JERSEY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOR MEDSYSTEMS, INC.;REEL/FRAME:019955/0487
Effective date: 20070306
Owner name: INNOVATIONAL HOLDINGS LLC,NEW JERSEY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOR MEDSYSTEMS, INC.;REEL/FRAME:019955/0487
Effective date: 20070306
Nov 18, 2009ASAssignment
Owner name: INNOVATIONAL HOLDINGS LLC, NEW JERSEY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOR MEDSYSTEMS, INC.;REEL/FRAME:023538/0021
Effective date: 20070306
Owner name: INNOVATIONAL HOLDINGS LLC,NEW JERSEY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CONOR MEDSYSTEMS, INC.;REEL/FRAME:023538/0021
Effective date: 20070306